AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26241948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buffer only)
Number of subjects: 32
Study 26241948 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine
Number of subjects: 32
Study 26241948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23252875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1820
Study 21196104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (500/20 μg, b.i.d.)
Number of subjects: 620
Study 18487565 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with carboplatin (AUC, 6) and paclitaxel (225 mg/m(2)); followed by weekly carboplatin (AUC, 2) and paclitaxel (45 mg/m(2)) with 74 Gy of TRT
Number of subjects: 69
Study 18487565 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy with carboplatin (AUC, 5) and gemcitabine (1,000 mg/m(2)); followed by biweekly gemcitabine (35 mg/m(2)) with 74 Gy of TRT
Number of subjects: 69
Study 16562348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mammography intervention
Number of subjects: 499
Study 12708902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin (low-molecular-weight heparin) administered subcutaneously at a fixed daily dosage of 1750 U
Number of subjects: 1073
Study 12708902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study 11027925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 62
Study 11027925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8884861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate
Number of subjects: 40
Study 8884861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex)
Number of subjects: 40
Study 8884861 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline (Haemaccel)
Number of subjects: 40
Study 8884861 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 4%
Number of subjects: 40
Study 1728634 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Number of subjects: 0
Study 1728634 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulfate
Number of subjects: 0
Study 1728634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured adult human keratinocytes treated with retinoic acid
Number of subjects: 0
Study 4029877 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram of iodine
Number of subjects: 35
Study 4029877 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microgram of L-thyroxine
Number of subjects: 35
Study 4029877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30943515 — intervention group
Group type: EXPERIMENTAL
Intervention: pre‐OL‐HDF
Number of subjects: 38
Study 30943515 — intervention group
Group type: COMPARATOR
Intervention: CHD
Number of subjects: 38
Study 28205417 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow tempo (84 bpm)
Number of subjects: 10
Study 28205417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast tempo (112 bpm)
Number of subjects: 10
Study 27604474 — intervention group
Group type: EXPERIMENTAL
Intervention: Early precut sphincterotomy
Number of subjects: 101
Study 27604474 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic duct stent placement
Number of subjects: 101
Study 24578449 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative glutamine administration
Number of subjects: 22
Study 24578449 — intervention group
Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 22
Study 22581299 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical transcatheter aortic valve implantation (a‐TAVI)
Number of subjects: 70
Study 22581299 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 70
Study 20220522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/12 reporting (time-sampled)
Number of subjects: 2
Study 20220522 — intervention group
Group type: COMPARATOR
Intervention: 12/12 reporting (continuous-time)
Number of subjects: 2
Study 18856077 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (minimum of three days a week for eight weeks)
Number of subjects: 0
Study 16380702 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise on a stationary bicycle
Number of subjects: 43
Study 14578687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 25 microg/m2 as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Number of subjects: 55
Study 14578687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 120 microg/m2 as a 72 h continuous infusion every 2 weeks (Regimen II)
Number of subjects: 55
Study 14578687 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Regimen I and Regimen II
Number of subjects: 55
Study 10474085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 32
Study 10474085 — intervention group
Group type: COMPARATOR
Intervention: Preoperative autologous blood donation (PAD)
Number of subjects: 32
Study 10474085 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH for unilateral knee replacement
Number of subjects: 32
Study 10474085 — intervention group
Group type: COMPARATOR
Intervention: PAD for unilateral knee replacement
Number of subjects: 32
Study 10474085 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH for bilateral/revision procedures
Number of subjects: 32
Study 10474085 — intervention group
Group type: COMPARATOR
Intervention: PAD for bilateral/revision procedures
Number of subjects: 32
Study 8598356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromodeoxyuridine labeling index (BrdUrd LI)
Number of subjects: 200
Study 8598356 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 200
Study 8598356 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky performance score
Number of subjects: 200
Study 8103770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg, orally, at -60 min) plus GHRH (1 microgram/kg, iv, at 0 min)
Number of subjects: 24
Study 8103770 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (30 g, iv, from 0-30 min) plus GHRH (1 microgram/kg, iv, at 0 min)
Number of subjects: 24
Study 8103770 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 24
Study 3538986 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary suture of the common bile duct
Number of subjects: 80
Study 3538986 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage of the common bile duct
Number of subjects: 80
Study 29518230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness for Pain and Performance Enhancement (MPPE) - Acceptance and Commitment Therapy-based program; six sessions over 2 weeks.
Number of subjects: 373
Study 29518230 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment services (control group); physical therapy, medical interventions, and psychoeducational groups.
Number of subjects: 373
Study 27542236 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 grams of vitamin D3 enriched salmon (high D3+high K1) two times/week
Number of subjects: 122
Study 27542236 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 grams of vitamin D3 enriched salmon (low D3+high K1) two times/week
Number of subjects: 122
Study 27542236 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 grams of vitamin D3 enriched salmon (high D3+low K1) two times/week
Number of subjects: 122
Study 27542236 — intervention group
Group type: COMPARATOR
Intervention: 800 IU vitamin D and 1000 mg calcium/day (tablet group)
Number of subjects: 122
Study 24754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammario-radial endoscopic group
Number of subjects: 300
Study 24754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aorto-radial endoscopic group
Number of subjects: 300
Study 24754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammario-radial open surgery group
Number of subjects: 300
Study 24754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aorto-radial open surgery group
Number of subjects: 300
Study 24754891 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 300
Study 22954508 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin 75 mg/m², ifosfamide 5 g/m², lenograstim)
Number of subjects: 351
Study 22954508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 351
Study 22954508 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin, ifosfamide)
Number of subjects: 351
Study 20384716 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug (new antiepileptic drugs)
Number of subjects: 11
Study 20384716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19025610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual sugar (SLS)
Number of subjects: 23
Study 19025610 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 10% glucose (IVG)
Number of subjects: 23
Study 15858602 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (50 mumol/kg/day, intravenously until infants tolerated 16 ml/day of feeds)
Number of subjects: 63
Study 15858602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 15858602 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 63
Study 14634414 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride 2 mg
Number of subjects: 107
Study 14634414 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride 3 mg
Number of subjects: 107
Study 14634414 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (dose increased from 2 to 3 mg)
Number of subjects: 107
Study 14634414 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (overall response)
Number of subjects: 107
Study 14634414 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of apomorphine hydrochloride
Number of subjects: 107
Study 10463681 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine (inactivated, BIKEN), administered in two dosing regimens (days 0, 7, and either 14 or 30)
Number of subjects: 538
Study 10463681 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine (inactivated, BIKEN)
Number of subjects: 538
Study 8020876 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-aggregation factor inhibitor (single doses)
Number of subjects: 12
Study 8020876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial single-blind period)
Number of subjects: 12
Study 2920630 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrugated drain
Number of subjects: 30
Study 2920630 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrugated plus Shirley sump drain
Number of subjects: 30
Study 2920630 — intervention group
Group type: COMPARATOR
Intervention: Both drainage methods
Number of subjects: 30
Study 2920630 — intervention group
Group type: COMPARATOR
Intervention: Higher than 12 cm anastomosis
Number of subjects: 30
Study 2920630 — intervention group
Group type: COMPARATOR
Intervention: Coloanal anastomosis
Number of subjects: 30
Study 1149486 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 77
Study 1149486 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene
Number of subjects: 77
Study 1149486 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 77
Study 31479396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-Free Vaginal Tape
Number of subjects: 224
Study 31479396 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylamide Hydrogel
Number of subjects: 224
Study 31340056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 382
Study 31340056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 31340056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (Physicians)
Number of subjects: 382
Study 31340056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Physicians)
Number of subjects: 382
Study 31340056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia occurrence
Number of subjects: 382
Study 31340056 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to clinical stability
Number of subjects: 382
Study 29354914 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 29354914 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 60
Study 26160250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 74
Study 26160250 — intervention group
Group type: COMPARATOR
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 74
Study 23238423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐VREM feedback (FB)
Number of subjects: 80
Study 21988576 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 194
Study 21988576 — intervention group
Group type: COMPARATOR
Intervention: Counseling as usual (CAU)
Number of subjects: 194
Study 18243412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anode right/cathode left)
Number of subjects: 23
Study 18243412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anode left/cathode right)
Number of subjects: 23
Study 18243412 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 23
Study 18243412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (both conditions)
Number of subjects: 23
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI risk classes II and III
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of medical or psychosocial contraindications to outpatient treatment
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid conditions not contained in the PSI (cognitive impairment, history of coronary artery disease, diabetes mellitus, pulmonary disease)
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilobar radiographic infiltrates
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Home therapy with oxygen, corticosteroids, or antibiotics before presentation
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: No identifiable risk factors for hospitalization other than PSI risk class II or III
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of one or more contraindications to outpatient treatment
Number of subjects: 1889
Study 16808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of low-risk patients in the outpatient setting
Number of subjects: 1889
Study 12774577 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-bevel needle for subcutaneous administration
Number of subjects: 0
Study 11045835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous application of soybean oil
Number of subjects: 60
Study 11045835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cutaneous treatment)
Number of subjects: 60
Study 9315170 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial color Doppler sonography
Number of subjects: 12
Study 7969673 — intervention group
Group type: EXPERIMENTAL
Intervention: Living related donor kidney transplant
Number of subjects: 8
Study 7969673 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 8
Study 3304412 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone (Solumedrone Upjohn Limited) given intravenously immediately preoperatively
Number of subjects: 20
Study 3304412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3304412 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone
Number of subjects: 20
Study 29945470 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-building intervention
Number of subjects: 94
Study 29945470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 29945470 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report MVPA
Number of subjects: 94
Study 28720592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (20 weeks)
Number of subjects: 60
Study 28720592 — intervention group
Group type: COMPARATOR
Intervention: Nontraining (control group, n = 15)
Number of subjects: 60
Study 26225845 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz tACS
Number of subjects: 26
Study 26225845 — intervention group
Group type: EXPERIMENTAL
Intervention: 20Hz tACS
Number of subjects: 26
Study 26225845 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 26
Study 26225845 — intervention group
Group type: COMPARATOR
Intervention: 35Hz tACS
Number of subjects: 26
Study 23103430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing training 3 times weekly for 12 weeks
Number of subjects: 24
Study 23103430 — intervention group
Group type: COMPARATOR
Intervention: Group music appreciation and relaxation for 12 weeks
Number of subjects: 24
Study 20653378 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Patients (VP)
Number of subjects: 49
Study 20653378 — intervention group
Group type: COMPARATOR
Intervention: Regular exams
Number of subjects: 49
Study 20653378 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-SP (delayed assessments)
Number of subjects: 49
Study 20653378 — intervention group
Group type: COMPARATOR
Intervention: Regular exams (delayed assessments)
Number of subjects: 49
Study 18416072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of acupuncture and Chinese medicines
Number of subjects: 93
Study 18416072 — intervention group
Group type: COMPARATOR
Intervention: Western medicines
Number of subjects: 93
Study 17021267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 8
Study 17021267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation (PO)
Number of subjects: 8
Study 17021267 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 8
Study 14656060 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation
Number of subjects: 0
Study 14656060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory proprioceptive stimulation
Number of subjects: 0
Study 10817313 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge programme
Number of subjects: 204
Study 10817313 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare (Control)
Number of subjects: 204
Study 8872691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (10 micrograms) followed by 12 ml of saline
Number of subjects: 40
Study 8872691 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (12 ml of 0.25% bupivacaine)
Number of subjects: 40
Study 1642922 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen with fentanyl
Number of subjects: 20
Study 1642922 — intervention group
Group type: COMPARATOR
Intervention: Oxygen and air (FIO2 = 0.5) with fentanyl
Number of subjects: 20
Study 6288627 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar (5 or 10 g) in aqueous solution
Number of subjects: 0
Study 6288627 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar (mixed with a test meal)
Number of subjects: 0
Study 6288627 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran (any dosage)
Number of subjects: 0
Study 30798104 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 0
Study 30798104 — intervention group
Group type: COMPARATOR
Intervention: Active control groups
Number of subjects: 0
Study 30259703 — intervention group
Group type: EXPERIMENTAL
Intervention: AX (astaxanthin 12 mg, tocotrienol 10 mg, zinc 6 mg)
Number of subjects: 42
Study 30259703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26843086 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4212 (subcutaneous doses of 5, 15, 60, 150, or 300 mg; intravenous dose of 300 mg)
Number of subjects: 0
Study 26843086 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab (subcutaneous)
Number of subjects: 0
Study 26843086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoassay (RIA)
Number of subjects: 66
Study 24796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 66
Study 24796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous mobility shift assay (HMSA)
Number of subjects: 66
Study 24796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cell-based reporter gene assay (RGA)
Number of subjects: 66
Study 24796769 — intervention group
Group type: EXPERIMENTAL
Intervention: All assays
Number of subjects: 66
Study 21593352 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g l-glutamine (Gln-30)
Number of subjects: 15
Study 21593352 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g L-glutamine (Gln-15)
Number of subjects: 15
Study 21593352 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SIT
Number of subjects: 15
Study 21593352 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SIT and 15 g L-glutamine (SIT+Gln-15)
Number of subjects: 15
Study 21593352 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study 19920419 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 and T3 thoracic RF thermolesion
Number of subjects: 50
Study 19920419 — intervention group
Group type: COMPARATOR
Intervention: T2 thermolesion with local application of 0.5 mL of 6% phenol
Number of subjects: 50
Study 16834836 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg for 8 weeks
Number of subjects: 823
Study 16834836 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg for 12 weeks (controlled patients)
Number of subjects: 823
Study 16834836 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day
Number of subjects: 823